Editorial: Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment by Jai Prakash & Kristian Pietras
May 2016 | Volume 6 | Article 1211
editorial
published: 17 May 2016
doi: 10.3389/fonc.2016.00121
Frontiers in Oncology | www.frontiersin.org
Edited by: 
Yisong Wang, 
National Institute of Health, USA
Reviewed by: 
Justin Lathia, 
Cleveland Clinic, USA
*Correspondence:
Jai Prakash  
j.prakash@utwente.nl
Specialty section: 
This article was submitted to Cancer 
Molecular Targets and Therapeutics, 
a section of the journal 
Frontiers in Oncology
Received: 01 April 2016
Accepted: 02 May 2016
Published: 17 May 2016
Citation: 
Prakash J and Pietras K (2016) 
Editorial: Novel Targets and Targeting 
Technologies to Modulate Tumor 
Microenvironment. 
Front. Oncol. 6:121. 
doi: 10.3389/fonc.2016.00121
editorial: Novel targets and targeting
technologies to Modulate tumor 
Microenvironment
 
Jai Prakash1* and Kristian Pietras2
1 Targeted Therapeutics, Biomaterials, Science and Technology, MIRA Institute for Biomedical Technology and Technical 
Medicine, University of Twente, Enschede, Netherlands, 2 Department of Laboratory Medicine, Division of Translational 
Cancer Research, Lund University, Lund, Sweden
Keywords: tumor microenvironment, tumor stroma, microrNa, targeted therapeutics, cancer-associated 
fibroblasts, stromal cells
The Editorial on the Research Topic
Novel Targets and Targeting Technologies to Modulate Tumor Microenvironment
In recent years, there is an increasing attention on the impact of the tumor microenvironment (TME) 
on tumor initiation, progression, and metastasis (1). Malignant tumor cells and non-malignant 
stromal cells actively interact with each other and thereby create a tumor-supportive microenviron-
ment (2). TME is composed of extracellular matrix and several cell types, such as cancer-associated 
fibroblasts (CAFs), endothelial cells, pericytes, tumor-associated macrophages (TAMs), and other 
immune cells (1, 3). The literature has been continuously highlighting new aspects on the complexity 
of these cell types and their pro- and anti-tumorigenic roles in cancer. For instance, depletion of 
stroma in pancreatic cancer has been shown to induce tumor growth (4), in contrast to literature 
showing tumor-promoting effects of stroma (2). There is a continuous increase in revelations of novel 
cellular and extracellular targets in TME, such as new receptors, extracellular matrix, and microRNA 
(miRNAs). Modulation of these targets may lead to the development of new diagnostics and thera-
peutics for cancer. To reinforce these developments, it is crucial to involve targeting technologies, 
such as drug and gene-targeting technologies, to TME.
Ehnman and Larsson have reviewed the microenvironmental targets in sarcomas, which are rare 
malignant tumors in all age groups. Treatment of sarcoma has faced several failures in clinical trials, 
urging a need for developing novel targeted therapies in combination with current multimodality 
regimens. Vasculature cells (e.g., endothelial cells, pericytes), immune cells (e.g., M2-like mac-
rophages, lymphocytes), and fibroblast-like cells are the crucial stromal cells in sarcomas. In clinic, 
therapies have been focused on inhibiting angiogenesis (e.g., tyrosine kinase inhibitors, including 
VEGFRs, PDGFRs, and c-KIT) and immune modulation (e.g., monoclonal antibodies against 
RANK receptor). Several therapies that are under investigation focus on the inhibition of multiple 
kinases simultaneously.
Kuninty et al. highlight miRNAs as key therapeutic targets in TME. miRNAs, small endogenous 
non-protein-coding RNAs, are emerging as key molecules in the modulation of TME due to their 
capacity to control cellular processes by inhibiting the expression of multiple target genes. The review 
enlists miRNAs dysregulated in different stromal cells, including CAFs, TAMs, immune cells, and 
tumor vascular cells (endothelial cells, pericytes). Due to the inherent physicochemical properties of 
miRNA (negative charge and hydrophilicity), they cannot pass through the cell membrane. Therefore, 
novel miRNA delivery systems are crucial to develop in order to target miRNA/anti-miRNA into 
stromal cells. Delivery strategies based on non-viral delivery systems, such as liposomes, lipoplexes, 
and polyplexes, are the state-of-the-art carriers to deliver miRNA.
2Prakash and Pietras Targeting Tumor Microenvironment
Frontiers in Oncology | www.frontiersin.org May 2016 | Volume 6 | Article 121
Elkhattouti et al. have focused on the role of stromal fibroblasts 
in tumorigenesis in age-related cancer. With advanced age, stroma 
generates a pro-tumorigenic microenvironment composed of 
cytokines, chemokines, and high energy metabolites. These 
factors drive the age-related cancer initiation and maintain its 
progression. With ageing of stroma, stromal fibroblasts become 
senescent so-called senescence-associated secretory phenotype 
(SASP) and contribute to tumor progression. Local stromal 
delivery of IL-12, an antitumor cytokine targeting immunosup-
pressive mechanisms, and intervention into the processes, such as 
fibroblast-fueled metabolites to cancer cells, are proposed as vital 
strategies to inhibit stromal tumorigenic activities.
Venning et al. have highlighted the role of ECM in different 
processes of metastatic spread and benefits of targeting ECM to 
prevent cancer progression. Key ECM players, such as periostin, 
tenascin C, hyaluronan, versican, and collagen-I are involved in 
the metastatic process. Many ECM proteins are involved in the 
induction of EMT in tumor cells by activating their signaling 
and helping them escape the primary tumor to blood. Within the 
blood, the ECM protein fibrinogen forms complexes with platelets 
and protects tumor cells from immune surveillance. Furthermore, 
at the metastatic site, ECM deposition and remodeling facilitates 
the outgrowth of metastasis. Targeting ECM proteins specifically 
using antibodies, peptides, or aptamers have been shown to target 
and block metastasis formation.
Most tumors are abnormal in the structure of the tumor 
vasculature and stroma. Gkretsi et al. highlight the remodeling 
TME to improve cancer therapy. Abnormal tumor vasculature, as 
a result of angiogenesis and ECM deposition, severely affects the 
accumulation of chemotherapies into tumors. Several strategies to 
remodel TME have been proposed, including vascular normali-
zation using anti-VEGF therapies to improve drug delivery and 
stress alleviation using angiotensin receptor blockers to reduce 
intratumoral pressure. The latter approaches have been shown 
to improve the effect of chemotherapies and nanomedicines in 
preclinical models.
Boonstra et al. have proposed an interesting approach to uti-
lize stroma targeting for image-guided surgery. Image-guided 
oncologic surgery (IGOS) assists the surgeon to distinguish 
tumor tissue from normal tissue during operation. Currently, 
fluorescent dyes in the near-infrared range are used in clinic, 
either in free form or conjugated to a ligand (antibody, pep-
tide) against targets present on tumor vasculature (αvβ3) or 
tumor cells (targets: EGFR, EpCAM). However, stromal cells 
as targets are not commonly used for IGOS. Targeting to CAFs 
and macrophages can be an attractive possibility to identify 
stroma as a margin and use for surgical removal of the whole 
tumor mass.
The research article by Yan et al. show the design of a cancer-
selective peptide and its application as a hybrid peptide PTS for 
rapid imaging of tumors preclinically. A hybrid peptide consisting 
of a cell-penetrating peptide and αvβ3-binding peptide was syn-
thesized and labeled with near-infrared dye. The hybrid peptide 
showed more cellular uptake in vitro compared to individual pep-
tides. In vivo using NIR imaging, the hybrid peptide was shown 
to be accumulated into tumors to a greater extent compared to 
the individual peptides. This approach shows the applicability of 
using combined targeting peptides for molecular imaging that 
could be translated into clinics in future.
In conclusion, this special issue highlights the key elements 
of TME; in particular, stromal targets such as miRNA, kinase 
pathways, and ECM proteins are highlighted to design novel 
therapeutics against cancer. In addition, targeting technologies to 
deliver miRNA as therapeutics and imaging probes for molecular 
imaging and image-guided surgery directing to stroma are also 
highlighted in this review issue. In future, integration of stromal 
targets with targeting technologies will pave new ways to utilize 
stroma for tumor diagnosis, surgery, and treatment.
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